Literature DB >> 12639706

Regulation of hepatobiliary excretion of sinomenine by P-glycoprotein in Sprague-Dawley rats.

Tung-Hu Tsai1, Jhy-Wen Wu.   

Abstract

Sinomenine, an herbal ingredient isolated from Sinomenium acutum, is used for the amelioration of arthritis. Using microdialysis and a specially constructed hepato-duodenal shunt probe, the present study investigated the pharmacokinetics of sinomenine in rat blood and bile and the effects of P-glycoprotein modulation and cytochrome P450 inhibition. The results indicated that the pharmacokinetics of sinomenine in rat blood appeared to be dose dependent in the 3 to 30 mg/kg range. The disposition of sinomenine in the bile exhibited a slow elimination phase, reaching a peak concentration in 20-40 min following intravenous administration. The area under the concentration versus time curves (AUC's) for sinomenine in the bile were significantly greater than those in the blood at dosages of 3, 10, and 30 mg/kg with the blood-to-bile distribution ratios (k = AUC(bile) / AUC(blood)) being 3.85 +/- 0.29 and 3.52 +/- 0.28 at 10 and 30 mg/kg, respectively, indicating active hepatobiliary excretion. Coadministration with 20 mg/kg of cyclosporin A 10 min prior to sinomenine administration resulted in a significant reduction of the bile AUC's for the dosages of 10 and 30 mg/kg., resulting in the bile/blood distribution ratio being significantly reduced to 0.47 +/- 0.05 and 0.49 +/- 0.05, respectively. On the other hand, proadifen treatment increased both the blood and bile AUC's, resulting in insignificant effects on the blood-to-bile distribution ratios. In conclusion, our results indicated that sinomenine underwent active hepatobiliary elimination which may be regulated by the P-glycoprotein and that P-450 was likely involved in its metabolism.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12639706     DOI: 10.1016/s0024-3205(03)00118-8

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

1.  Sex-related differences in safety profiles, pharmacokinetics and tissue distribution of sinomenine hydrochloride in rats.

Authors:  Hong Huang; Er-Bing Zhang; Ou-Yang Yi; Han Wu; Guiming Deng; Yu-Ming Huang; Wen-Liang Liu; Jian-Ye Yan; Xiong Cai
Journal:  Arch Toxicol       Date:  2022-08-30       Impact factor: 6.168

2.  Sinomenine sensitizes multidrug-resistant colon cancer cells (Caco-2) to doxorubicin by downregulation of MDR-1 expression.

Authors:  Zhen Liu; Zhi-Jun Duan; Jiu-Yang Chang; Zhi-Feng Zhang; Rui Chu; Yu-Ling Li; Ke-Hang Dai; Guang-Quan Mo; Qing-Yong Chang
Journal:  PLoS One       Date:  2014-06-05       Impact factor: 3.240

3.  Comparative pharmacokinetics study of sinomenine in rats after oral administration of sinomenine monomer and Sinomenium acutum extract.

Authors:  Mao-Fan Zhang; Yan Zhao; Kun-Yu Jiang; Long Han; Xiao-Yue Lu; Xin Wang; Lan Zuo; Sheng-Nan Meng
Journal:  Molecules       Date:  2014-08-12       Impact factor: 4.411

4.  Antinociceptive Effects of Sinomenine Combined With Ligustrazine or Paracetamol in Animal Models of Incisional and Inflammatory Pain.

Authors:  Tianle Gao; Tao Li; Wei Jiang; Weiming Fan; Xiao-Jun Xu; Xiaoliang Zhao; Zhenming Yin; Huihui Guo; Lulu Wang; Jun Gao; Yanxing Han; Jian-Dong Jiang; Danqiao Wang
Journal:  Front Physiol       Date:  2021-02-09       Impact factor: 4.566

Review 5.  Targeting Nrf2-Mediated Oxidative Stress Response in Traumatic Brain Injury: Therapeutic Perspectives of Phytochemicals.

Authors:  An-Guo Wu; Yuan-Yuan Yong; Yi-Ru Pan; Li Zhang; Jian-Ming Wu; Yue Zhang; Yong Tang; Jing Wei; Lu Yu; Betty Yuen-Kwan Law; Chong-Lin Yu; Jian Liu; Cai Lan; Ru-Xiang Xu; Xiao-Gang Zhou; Da-Lian Qin
Journal:  Oxid Med Cell Longev       Date:  2022-04-04       Impact factor: 6.543

Review 6.  Potential therapeutic effects and pharmacological evidence of sinomenine in central nervous system disorders.

Authors:  Hongxiang Hong; Xu Lu; Qun Lu; Chao Huang; Zhiming Cui
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.